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since January 1st, 2011.The correlation coefficient was calculated to assess the linear 
correlation of the additional clinical benefit of an oncology product evaluated by the 
G-BA and the HAS, both measured by an arbitrary score scale from 1 (best outcome) 
to 5 (worst outcome). The G-BA score was taken from the “added benefit” rating, and 
the HAS score was determined by the ASMR rating. The additional clinical benefit is 
determined by the clinical data (efficacy, safety and QoL) provided in both GER and 
FRA. The correlation coefficient between the incremental OS benefit and the HTA 
appraisal outcome in each market was also calculated. Results: The correlation 
coefficient of HTA decisions by the G-BA and the HAS for oncology products is 0.73. 
In Germany, the magnitude of incremental OS benefit negatively correlates with 
the G-BA score (correlation coefficient = -0.83). Similar results were also observed 
in France, where the correlation coefficient between the incremental OS benefit 
and the HAS score was -0.66. Interestingly, the G-BA score forms clear “steps” that 
highly correlate with the incremental OS benefit based on our empirical analysis. 
To “step up” from score 3 to score 2, an incremental OS benefit of 3 months appears 
to serve as a threshold. ConClusions: The negative linear correlation between 
the incremental OS benefit and the HTA rating in GER and FRA suggests that the 
additional clinical benefit, especially the incremental OS benefit is a major factor 
in determining the HTA outcome in GER and FRA.
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BACkgRound: Health technology assessment (HTA) agencies summarize infor-
mation about the medical, social, economic and ethical issues related to the use 
of health technologies in a systematic, transparent, unbiased, and robust manner. 
Several global organizations exist to provide guidance based on clinical effective-
ness, safety, and cost-effectiveness relative to alternative technologies. oBjeCtives: 
We compared recommendations made by the pan-Canadian Oncology Drug 
Review (pCODR) to other HTA agencies. Methods: Publicly accessible recom-
mendations were reviewed: Australia (Pharmaceutical Benefits Advisory Committee 
(PBAC), www.pbs.gov.au), Canada (pCODR, www.pcodr.ca), Sweden (Dental and 
Pharmaceutical Benefits Agency (TLV), www.tlv.se) and UK (National Institute for 
Health and Care Excellence (NICE), www.nice.org.uk). Additional information was 
obtained from the www.reimbursementdecisions.com database. Results: pCODR 
had thirteen product reviews in common with PBAC, six with TLV, and thirteen with 
NICE. Overall, pCODR unlike the other agencies, was most likely to provide a positive 
recommendation, albeit, conditional on improvement of cost-effectiveness. In gen-
eral, negative recommendations made by pCODR based on clinical concerns were 
often mirrored by the other agencies. Similarly, findings by pCODR of positive clini-
cal benefit but with concerns over cost-effectiveness were often reciprocated by the 
other agencies in conditional positive recommendations (i.e., price reductions or risk 
sharing) or by negative recommendations due to cost-effectiveness. ConClusions: 
The recommendations by these agencies reflected significant agreement regarding 
overall clinical and economic benefit. Although discordance in recommendation 
wording between agencies was noted, these likely reflected process and funding dif-
ferences rather than a difference in the perceived product value. pCODR differs from 
other agencies in its clear distinction between evidence review and funding negotia-
tions. As such, pCODR can positively recommend a product with acceptable clinical 
value conditional on improved cost-effectiveness without specifying the degree of 
price reduction needed or negotiating such discounts. This creates an environment 
that favours early global launch in Canada without delays for price negotiation.
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oBjeCtives: Cancer is the second lead cause of death in Brazil, with growing social 
and economic burden. According to Brazilian National Institute of Cancer/INCA, 
576.580 new cases are expected in 2014. This study aimed better understand oncol-
ogy landscape in Brazil using a real-world data source. Methods: Data reported 
from 2009-2013 was taken from RHC-INCA – an open national patient registry data-
base – for the following cancers: gastric (GC/ICD16); colorectal (CRC/ICD18-21); lung 
(LC/ICD33-34); breast (BC/ICD50); cervical (CC/ICD53) and ovarian (OC/ICD56). Only 
adult patients with TNM classification at diagnosis were included. Records labeled 
as ‘not informed’ or ‘not applicable’ were excluded. This study assessed distribution 
of those cancers according to gender; age group; stage at diagnosis for all patients; 
treatment choice and 1-year outcomes in stage IV patients with non-recorded previ-
ous treatment. Results: Gender (male/female): GC–65.2%/34.8%; CRC–48.3%/51.7%; 
LC–62.2%/37.8%; BC–1.3%/98.7%. Highest frequency ages: males GC–60-74 years; 
CRC–55-69 years; LC–55-74 years; females GC–55-69 years; CRC–55-69 years; LC–55-
69 years; BC–45-59 years; CC–35-49 years; OC–45-59 years. Stage at diagnosis (0/I/
II/III/IV): GC–0.3%/10.7%/13.9%/24.8%/50.3%; CRC–0.6%/8.7%/29.5%/35.5%/25.7%; 
LC–0.1%/5.3%/6.2%/37.0%/51.4%; BC–3.0%/19.1%/36.8%/32.2%/8.8%; CC–17.5%/1
5.6%/26.3%/34.2%/6.3%; OC–0.0%/25.0%/8.5%/41.9%/24.6%. Regions with highest 
frequency of advanced cases (stages III/IV): GC–North(83.3%); CRC–South(65.1%); 
North(64.6%); LC–North(91.6%) and Northeast(91.1%); BC–North(52.2%) and 
West Center(51.6%); CC–South(49.3%) and North(45.8%); OC–South(69.9%); 
Northeast(67.3%). Stage IV treatment choice (chemotherapy alone or combined 
with another procedure/non-chemotherapy procedures): GC–73.4%/26.6%; CRC–
81.3%/18.7%; LC–75.1%/24.9%; BC–76.6%/23.4%; CC–63.5%/36.5%; OC–83.5%/16.5%. 
1-year outcomes (remission or controlled disease/progression, therapy unfeasibil-
ity or death): GC–26.9%/73.1%; CRC–34.3%/65.7%; LC–22.7%/77.3%; BC–38.4%/61.6%; 
CC–34.6%/65.4%; OC–35.1%/64.9%. ConClusions: Results evidence epidemiological 
differences between each type of cancer and amongst country regions. Regarding 
metastatic disease the majority of treatment strategies include chemotherapy; 
furthermore outcomes are poor with less than 40% of patients in remission or 
controlled disease after first year of treatment. The study had limitation regarding 
that São Paulo state data are not included in RHC-INCA.
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oBjeCtives: To assess the impact on medical decision-making by an in-vitro diag-
nostic test that predicts the risk of clinically recurrent prostate cancer following 
prostatectomy. Methods: ProsVue™ is an FDA-cleared prognostic test that meas-
ures the linear slope of 3 ultrasensitive prostate-specific antigen levels over time. 
In the 510(k) clinical study, ProsVue was the strongest independent predictor of 
clinically recurrent prostate cancer in a 304-man cohort study. However, its clini-
cal utility in adjuvant treatment decision-making has not yet been demonstrated. 
We prospectively enrolled men treated by radical prostatectomy in a multicenter, 
IRB-approved clinical trial. At postsurgical followup, urologist investigators (N= 17) 
stratified each of their patients into a low, intermediate or high risk group for cancer 
recurrence based on clinicopathologic findings and documented their initial treat-
ment plan. We employed the CAPRA-S postprostatectomy nomogram to standardize 
risk assessments across the investigative sites. After a patient’s ProsVue result was 
reported, urologists recorded whether or not the patient’s initial treatment plan was 
changed. The proportion of cases referred for secondary treatment before and after 
ProsVue and the significance of the difference was determined. Results: Of 225 
men reported; 128 (56.9%) were stratified into intermediate and high CAPRA-S risk 
groups. Investigators reported that they would have referred 41/128 (32.0%) at-risk 
men for adjuvant radiotherapy without ProsVue information. After results were 
known, investigators referred only 15/128 (11.7%) men. The difference in proportions 
(-20.3%, 95% confidence interval [CI] -29.9 to -10.3%) is significant (p < 0.0001). Odds 
of a referral after the ProsVue result was reported was significantly reduced (Odds 
Ratio = 0.28, 95% CI 0.15 to 0.54, p < 0.0001). ConClusions: ProsVue has significant 
clinical utility in high-risk postprostatectomy cancer patients. A ProsVue result ≤ 2.0 
pg/mL/month significantly reduced the proportion of urologists’ recommendations 
for adjuvant radiotherapy. Followup studies are needed to demonstrate whether or 
not ProsVue utilization reduces health care costs.
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oBjeCtives: Relatively little is known about physicians’ decisions to adopt and 
use GEP to aid in treatment recommendations. The objective of this study was to 
determine the association between specific characteristics of a GEP assay, Oncotype 
DX and oncologists’ intention to use this assay in making treatment recommen-
dations for breast cancer patients. Methods: A nationally representative sam-
ple of oncologists treating breast cancer patients was surveyed. Linear regression 
analysis was performed to establish the association between physicians’ per-
ceptions and intentions to use Oncotype DX. Results: A total of 119 completed 
surveys were received yielding a response rate of 44.1%. Of the Oncotype DX test 
characteristics evaluated, ‘validity of the test’ (p= 0.006) and ‘use of Oncotype DX 
by fellow Oncologists’ (p= 0.0068) were significantly associated with oncologists’ 
use of the assay. Oncologists’ intention to use Oncotype DX increased consist-
ently with their perceptions about its usefulness (β = 0.222). Insurance status of 
the patients was also significantly associated with physicians’ use of Oncotype DX 
(p= 0.008). ConClusions: We report a novel application of an adapted technology 
acceptance model to understand decision-making by oncologists who treat breast 
cancer patients surrounding the use of GEP in making treatment recommendations. 
Our study provides insights into the characteristics and innovation factors of a 
particular genomic diagnostic that affect decision-making by oncologists who treat 
breast cancer patients. Our findings have implications for knowledge translation 
efforts related to molecular genomic diagnostics and to the development of future 
molecular genomic diagnostics.
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oBjeCtives: Overall objectives are to examine symptom burden and quality of life 
in prospectively accrued patients with advanced non-small cell lung cancer (NSCLC), 
treated in real world settings. The present report examines treatment patterns and 
baseline characteristics of an initial sample of 95 patients. Methods: Patients 
starting first line treatment of stage IIIB/IV NSCLC were prospectively accrued and 
consented at 30 US-based community oncology settings. Eligible patients received 
one of four regimens: A: pemetrexed with cisplatin or carboplatin; B: bevacizumab 
with chemotherapy doublet; C: chemotherapy doublet; D: bevacizumab, pemetrexed 
and carboplatin. Site staff collected baseline demographic and clinical informa-
tion, and patient-reported outcome and symptom measures at baseline and each 
office visit. Overall target enrollment is 225. Results: Of 95 patients, 40 (42%) were 
accrued in Regimen A, 17 (17.9%) in Regimen B, 13 (13.7%) in Regimen C, and 25 
(26.3%) in Regimen D. Patients were 54.7% male, 87.4% Caucasian, with mean age 
64.6 (±11.7). 15.8% had impaired performance status (ECOG 2+ or equivalent), with 
